Neurodegeneration Publications – Xenon Alzheimer’s Research
Wesley Brandao, Nimansha Jain, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Xin Bao, Javier R. Serrano, Eric Tycksen, Ana Durao, Jen-Li Barry, Caroline Baufeld, Dilansu Guneykaya, Xiaoming Zhang, Alexandra Litvinchuk, Hong Jiang, Neta Rosenzweig, Kristen M. Pitts, Michael Aronchik, Taha Yahya, Tian Cao, Marcelo Kenzo Takahashi, Rajesh Krishnan, Hayk Davtyan, Jason D. Ulrich, Mathew Blurton-Jones, Ilya Ilin, Howard L. Weiner, David M. Holtzman, Oleg Butovsky
Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy.
Sci. Transl. Med.17,eadk3690(2025).DOI:10.1126/scitranslmed.adk3690
Inhaled Xenon Modulates Microglia and Ameliorates Disease in Mouse Models of Amyloidosis and Tauopathy
AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. March 5-9, 2024. Lisbon, Portugal
Ilya Ilin, Wesley Brandao, Nimansha Jain, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Matthew Blurton-Jones, Howard L, Weiner, David M. Holtzman, Oleg Butovsky
The Neurodegeneration Publications section highlights key scientific studies supporting the use of xenon gas as a novel therapeutic approach for Alzheimer’s disease and related neurodegenerative disorders. These publications provide strong evidence of xenon’s ability to modulate brain immune responses and reduce disease pathology.
A landmark study published in Science Translational Medicine (2025) demonstrates that inhaled xenon significantly modulates microglial activity and improves disease outcomes in mouse models of amyloidosis and tauopathy. The study shows that xenon reduces neuroinflammation, restores microglial balance, and decreases pathological markers associated with Alzheimer’s disease.
Additional findings presented at the AD/PD 2024 International Conference further validate xenon’s therapeutic potential in neurodegeneration. These results highlight xenon’s ability to influence multiple disease pathways, including amyloid-beta accumulation and tau-related neurodegeneration.
Microglia play a central role in maintaining brain homeostasis, and their dysregulation is a key driver of neurodegenerative diseases. Xenon therapy directly targets these mechanisms by restoring microglial phenotype and reducing inflammatory signaling.
The growing body of research positions xenon gas inhalation as a promising multi-target therapeutic strategy for Alzheimer’s disease and other neurodegenerative conditions. General Biophysics continues to advance this research, bridging the gap between scientific discovery and future clinical applications.
What do these neurodegeneration publications show?
These studies demonstrate that xenon inhalation can modulate microglial activity and reduce disease pathology in models of Alzheimer’s and related conditions.
How does xenon affect Alzheimer’s disease?
Research shows xenon reduces amyloid and tau-related pathology while restoring microglial function and decreasing neuroinflammation.
Are these studies peer-reviewed?
Yes, key findings are published in leading journals such as Science Translational Medicine and presented at international conferences.
What is the significance of microglia in neurodegeneration?
Microglia regulate brain immune responses, and their dysfunction contributes to neuroinflammation and disease progression in Alzheimer’s and other disorders.
Is xenon therapy clinically available?
Xenon therapy is currently under research and development, with promising preclinical results supporting future clinical applications.